CO2023005260A2 - Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas - Google Patents

Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas

Info

Publication number
CO2023005260A2
CO2023005260A2 CONC2023/0005260A CO2023005260A CO2023005260A2 CO 2023005260 A2 CO2023005260 A2 CO 2023005260A2 CO 2023005260 A CO2023005260 A CO 2023005260A CO 2023005260 A2 CO2023005260 A2 CO 2023005260A2
Authority
CO
Colombia
Prior art keywords
enzymes
methods
fusion proteins
sulfoglucosamine sulfohydrolase
proteins
Prior art date
Application number
CONC2023/0005260A
Other languages
English (en)
Spanish (es)
Inventor
Mihalis Kariolis
Gunasekaran Kannan
Tina Giese
Cathal Mahon
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CO2023005260A2 publication Critical patent/CO2023005260A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CONC2023/0005260A 2020-10-14 2023-04-25 Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas CO2023005260A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063091800P 2020-10-14 2020-10-14
PCT/US2021/054860 WO2022081765A1 (en) 2020-10-14 2021-10-13 Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof

Publications (1)

Publication Number Publication Date
CO2023005260A2 true CO2023005260A2 (es) 2023-05-19

Family

ID=78725609

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0005260A CO2023005260A2 (es) 2020-10-14 2023-04-25 Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas

Country Status (17)

Country Link
US (2) US11884944B2 (cg-RX-API-DMAC7.html)
EP (1) EP4229192A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023545707A (cg-RX-API-DMAC7.html)
KR (1) KR20230086703A (cg-RX-API-DMAC7.html)
CN (1) CN116916947A (cg-RX-API-DMAC7.html)
AR (1) AR123788A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021362209B2 (cg-RX-API-DMAC7.html)
CA (1) CA3197506A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001034A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023005260A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230178A (cg-RX-API-DMAC7.html)
EC (1) ECSP23035251A (cg-RX-API-DMAC7.html)
IL (1) IL302029A (cg-RX-API-DMAC7.html)
MA (1) MA71661A (cg-RX-API-DMAC7.html)
MX (1) MX2023004335A (cg-RX-API-DMAC7.html)
PE (1) PE20231931A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022081765A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
TW202542190A (zh) * 2023-12-20 2025-11-01 美商戴納立製藥公司 包含酸性α—葡萄糖苷酶之融合蛋白及其方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
PL3219795T3 (pl) 2008-01-18 2024-09-16 Biomarin Pharmaceutical Inc. Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
BR112012033214B1 (pt) 2010-06-25 2020-11-03 Shire Human Genetic Therapies, Inc. uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランn−スルファターゼのcns送達のための方法および組成物
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
CA2842492A1 (en) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
MX367126B (es) 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
WO2014152940A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
US20150023956A1 (en) 2013-07-22 2015-01-22 Armagen Technologies, Inc. Methods and compositions for increasing enzyme activity in the cns
SMT201800511T1 (it) 2014-04-01 2018-11-09 Swedish Orphan Biovitrum Ab Publ Sulfamidasi modificata e sua produzione
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
MY207684A (en) 2015-12-08 2025-03-12 Regeneron Pharma Compositions and methods for internalizing enzymes
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
EP3419651B1 (en) 2016-02-24 2023-10-25 BioMarin Pharmaceutical Inc. Improved naglu fusion protein formulation
CA3033082A1 (en) 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
CN109641971B (zh) 2016-08-25 2023-04-04 Jcr制药股份有限公司 抗体融合蛋白的制造方法
EP3556399A1 (en) 2016-12-19 2019-10-23 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
TWI833178B (zh) * 2016-12-26 2024-02-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
MX2019007824A (es) 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
EP4628586A3 (en) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Transferrin receptor transgenic models
GB201702863D0 (en) 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
US20200157172A1 (en) 2017-07-07 2020-05-21 HANMl PHARM. CO., LTD. Novel therapeutic enzyme fusion protein and use thereof
WO2019032955A1 (en) 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
EP3708661A4 (en) 2017-12-22 2021-12-01 Hanmi Pharm. Co., Ltd. THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE
BR112020013921A2 (pt) * 2018-01-10 2020-12-01 Denali Therapeutics Inc. polipeptídeos de ligação ao receptor de transferrina e usos destes
WO2019145500A1 (en) 2018-01-26 2019-08-01 Swedish Orphan Biovitrum Ab (Publ) Method of treatment
CR20200566A (es) * 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
WO2019246071A1 (en) 2018-06-18 2019-12-26 Denali Therapeutics Inc. Fusion proteins comprising progranulin
CA3109763A1 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
EP3840781A1 (en) 2018-08-22 2021-06-30 Denali Therapeutics Inc. Anti-her2 polypeptides and methods of use thereof
AR119259A1 (es) * 2018-08-31 2021-12-09 Alector Llc Anticuerpos anti-cd33 y métodos de uso de los mismos
AU2020252554B2 (en) 2019-04-03 2026-05-28 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
WO2021158986A1 (en) 2020-02-07 2021-08-12 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
CA3170338A1 (en) 2020-02-19 2021-08-26 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins

Also Published As

Publication number Publication date
CL2023001034A1 (es) 2023-10-06
AU2026203601A1 (en) 2026-05-28
KR20230086703A (ko) 2023-06-15
JP2023545707A (ja) 2023-10-31
EP4229192A1 (en) 2023-08-23
US20240150736A1 (en) 2024-05-09
MA71661A (fr) 2025-05-30
CN116916947A (zh) 2023-10-20
US11884944B2 (en) 2024-01-30
CA3197506A1 (en) 2022-04-21
ECSP23035251A (es) 2023-10-31
TW202229547A (zh) 2022-08-01
AU2021362209B2 (en) 2026-02-12
AR123788A1 (es) 2023-01-11
US20230062800A1 (en) 2023-03-02
AU2021362209A1 (en) 2023-05-18
MX2023004335A (es) 2023-05-04
WO2022081765A1 (en) 2022-04-21
CR20230178A (es) 2023-07-26
PE20231931A1 (es) 2023-12-01
JP2026095522A (ja) 2026-06-11
IL302029A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
ECSP23035251A (es) Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
MX2024006720A (es) Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas
UY40421A (es) Formulación que comprende una enzima que cataliza la producción de óxido nítrico
CY1123676T1 (el) Συνθεσεις και μεθοδοι για την εσωτερικοποιηση ενζυμων
MX2019009191A (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas.
CL2018003148A1 (es) Proteínas de fusión y usos de las mismas.
PE20130648A1 (es) Tratamiento del sindrome de sanfilippo tipo b
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
CY1122128T1 (el) Θεραπεια ενζυμικης αντικαταστασης με κλιμακωση δοσης για αντιμετωπιση ανεπαρκειας σε οξινη σφιγγομυελιναση
BR112019012964A2 (pt) polipeptídeos multiméricos moduladores de célula t e métodos de uso dos mesmos
ES2532985T3 (es) Proteínas quiméricas de toxoide de Shiga
AR023214A1 (es) Variantes de alfa-amilasa
AR087091A1 (es) Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso
AR066199A1 (es) Metodo para reducir la concentracion del peptido amiloide beta
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2019013458A (es) Disminucion de homocisteina mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
MX2017001824A (es) Mutaciones en proteinas del grupo hierro-azufre que mejoran la utilizacion de xilosa.
MX2024007319A (es) Proteinas de fusion que comprenden enzimas de alfa-l-iduronidasa y metodos.
BRPI0518571A2 (pt) peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer
CO2021006432A2 (es) Enzimas de degradación de cistina/cisteína de primates modificadas por ingeniería genética para usos terápeuticos
BR112023017442A2 (pt) Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica
AR114938A1 (es) Variantes de expresión de cdkl5 y proteínas de fusión cdkl5
MX2024001689A (es) Un hla-b57 modificado que tiene niveles de expresion incrementados.